Ewha Med J.  2022 Apr;45(2):35-45. 10.12771/emj.2022.45.2.35.

Medication Adherence in Korean Patients with Inflammatory Bowel Disease and Its Associated Factors

• Oh K
• Kwon EJ
• Kim JH
• Kim K
• Lee JY
• Hong HS
• Hong SW
• Park JH
• Hwang SW
• Yang DH
• Ye BD
• Byeon JS
• Myung SJ
• Yang SK
• Park JY
• Park SH

• KMID: 2529434
• DOI: http://doi.org/10.12771/emj.2022.45.2.35

Abstract

Objectives
It is important that inflammatory bowel disease (IBD) patients adhere to their prescribed medication regimens to avoid the repeat exacerbations, complications, or surgeries associated with this disorder. However, there are few studies on medication adherence in patients with IBD, especially in Asian populations. So, we analyzed the factors associated with medication adherence in Korean IBD patients.
Methods
Patients who had been diagnosed with Crohn’s disease (CD) or ulcerative colitis (UC) more than 6 months previously and receiving oral medications for IBD were enrolled. Medication adherence was measured using the Medical Adherence Reporting Scale (MARS-5), a self-reported medication adherence measurement tool.
Results
Among 207 patients in the final study population, 125 (60.4%) had CD and 134 (64.7%) were men. The mean age was 39.63 years (SD, 13.16 years) and the mean disease duration was 10.09 years (SD, 6.33 years). The mean medication adherence score was 22.46 (SD, 2.86) out of 25, and 181 (87.4%) patients had score of 20 or higher. In multiple linear regression analysis, self-efficacy (β=0.341, P<0.001) and ≥3 dosing per day (β=–0.192 P=0.016) were revealed to be significant factors associated with medication adherence. Additionally, there was a positive correlation between self-efficacy and medication adherence (r=0.312, P<0.001). However, disease related knowledge, depression, and anxiety were not significantly associated with medication adherence.
Conclusion
To improve medication adherence among patients with IBD, a reduction in the number of doses per day and an improved self-efficacy will be helpful.

Keyword

Inflammatory bowel diseases; Medication adherence; Self efficacy; Korea

Reference

References

1. Mizoguchi E, Low D, Ezaki Y, Okada T. Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models. Intest Res. 2020; 18:151–167. DOI: 10.5217/ir.2019.09154. PMID: 32326669. PMCID: PMC7206339.

2. Kim JM, Cheon JH. Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases. Intest Res. 2020; 18:249–264. DOI: 10.5217/ir.2019.00128. PMID: 32295331. PMCID: PMC7385581.

3. Sood A, Kaur K, Singh A, Midha V, Mahajan R, Bansal N, et al. Trends of inflammatory bowel disease at a tertiary care center in northern India. Intest Res. 2021; 19:282–290. DOI: 10.5217/ir.2020.00010. PMID: 32806872. PMCID: PMC8322028.

4. Kaibullayeva J, Ualiyeva A, Oshibayeva A, Dushpanova A, Marshall JK. Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study. Intest Res. 2020; 18:430–437. DOI: 10.5217/ir.2019.00099. PMID: 32988164. PMCID: PMC7609398.

5. Park SH, Kim YJ, Rhee KH, Kim YH, Hong SN, Kim KH, et al. A 30- year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015. J Crohns Colitis. 2019; 13:1410–1417. DOI: 10.1093/ecco-jcc/jjz081. PMID: 30989166.

6. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012; 380:1590–1605. DOI: 10.1016/S0140-6736(12)60026-9.

7. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JE. Ulcerative colitis. Lancet. 2017; 389:1756–1770. DOI: 10.1016/S0140-6736(16)32126-2.

8. Yoo JH, Holubar S, Rieder F. Fibrostenotic strictures in Crohn’s disease. Intest Res. 2020; 18:379–401. DOI: 10.5217/ir.2019.09148. PMID: 32259917. PMCID: PMC7609387.

9. Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020; 14:4–22. DOI: 10.1093/ecco-jcc/jjz180. PMID: 31711158.

10. Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017; 11:769–784. DOI: 10.1093/ecco-jcc/jjx009. PMID: 28513805.

11. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004; 53:1471–1478. DOI: 10.1136/gut.2004.041616. PMID: 15361497. PMCID: PMC1774248.

12. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73:691–705. DOI: 10.1111/j.1365-2125.2012.04167.x. PMID: 22486599. PMCID: PMC3403197.

13. Tae CH, Jung SA, Moon HS, Seo JA, Song HK, Moon CM, et al. Importance of patients’ knowledge of their prescribed medication in improving treatment adherence in inflammatory bowel disease. J Clin Gastroenterol. 2016; 50:157–162. DOI: 10.1097/MCG.0000000000000431. PMID: 26501880.

14. Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2010; 105:525–539. DOI: 10.1038/ajg.2009.685. PMID: 19997092.

15. Kim MC, Jung YS, Song YS, Lee JI, Park JH, Sohn CI, et al. Factors associated with anxiety and depression in Korean patients with inactive inflammatory bowel disease. Gut Liver. 2016; 10:399–405. DOI: 10.5009/gnl15188. PMID: 26470768. PMCID: PMC4849693.

16. Son YJ, Won MH. Depression and medication adherence among older Korean patients with hypertension: mediating role of self-efficacy. Int J Nurs Pract. 2017; 23:e12525. DOI: 10.1111/ijn.12525. PMID: 28194846.

17. Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003; 98:1535–1544. DOI: 10.1111/j.1572-0241.2003.07522.x. PMID: 12873575.

18. Selinger CP, Eaden J, Selby W, Jones DB, Katelaris P, Chapman G, et al. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis. 2013; 7:e206–e213. DOI: 10.1016/j.crohns.2012.09.010. PMID: 23040449.

19. Keefer L, Kiebles JL, Taft TH. The role of self-efficacy in inflammatory bowel disease management: preliminary validation of a disease-specific measure. Inflamm Bowel Dis. 2011; 17:614–620. DOI: 10.1002/ibd.21314. PMID: 20848516. PMCID: PMC3005084.

20. Banerjee R, Pal P, Adigopula B, Reddy DN. Impact of demographic, clinical and psychosocial variables on drug adherence and outcomes in Indian patients with inflammatory bowel disease: cost is not the only factor! J Clin Gastroenterol. 2021; 55:e92–e99. DOI: 10.1097/MCG.0000000000001480. PMID: 33405436.

21. Lee J, Jee SR, Kim HW, Baek DH, Song GA, Moon W, et al. Factors associated with low adherence to oral 5-aminosalicylic acid in patients with ulcerative colitis. PLoS One. 2019; 14:e0214129. DOI: 10.1371/journal.pone.0214129. PMID: 30901362. PMCID: PMC6430391.

22. Horne R, Parham R, Driscoll R, Robinson A. Patients’ attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2008; 15:837–844. DOI: 10.1002/ibd.20846. PMID: 19107771.

23. Stone JK, Shafer LA, Graff LA, Lix L, Witges K, Targownik LE, et al. Utility of the MARS-5 in assessing medication adherence in IBD. Inflamm Bowel Dis. 2021; 27:317–324. DOI: 10.1093/ibd/izaa056. PMID: 32195533. PMCID: PMC7885329.

24. Kim JA, Kim ES, Lee EK. Evaluation of the chronic disease management program for appropriateness of medication adherence and persistence in hypertension and type-2 diabetes patients in Korea. Medicine. 2017; 96:e6577. DOI: 10.1097/MD.0000000000006577. PMID: 28383439. PMCID: PMC5411223.

25. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007; 39:175–191. DOI: 10.3758/BF03193146. PMID: 17695343.

26. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009; 41:1149–1160. DOI: 10.3758/BRM.41.4.1149. PMID: 19897823.

27. Yoon H, Yang SK, So H, Lee KE, Park SH, Jung SA, et al. Development, validation, and application of a novel tool to measure disease-related knowledge in patients with inflammatory bowel disease. Korean J Intern Med. 2019; 34:81–89. DOI: 10.3904/kjim.2017.104. PMID: 29172400. PMCID: PMC6325432.

28. Lee YJ, Kim YH, Kim HW. Preconception care program for women with inflammatory bowel disease using intervention mapping: a protocol for program development. Int J Environ Res Public Health. 2020; 17:9365. DOI: 10.3390/ijerph17249365. PMID: 33327583. PMCID: PMC7765051.

29. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67:361–370. DOI: 10.1111/j.1600-0447.1983.tb09716.x. PMID: 6880820.

30. Oh SM, Min KJ, Park DB. A study on the standardization of the hospital anxiety and depression scale for Koreans: a comparison of normal, depressed and anxious groups. J Korean Neuropsychiatr Assoc. 1999; 38:289–296.

31. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006; 23:577–585. DOI: 10.1111/j.1365-2036.2006.02809.x. PMID: 16480396.

32. Kim SB, Kim KO, Jang BI, Kim ES, Cho KB, Park KS, et al. Patients’ beliefs and attitudes about their treatment for inflammatory bowel disease in Korea. J Gastroenterol Hepatol. 2016; 31:575–580. DOI: 10.1111/jgh.13155. PMID: 26313162.

33. Lim JK, Lee YJ, Park JH. Medication-related knowledge and medication adherence in pediatric and adolescent patients with inflammatory bowel disease. J Korean Med Sci. 2020; 35:e92. DOI: 10.3346/jkms.2020.35.e92. PMID: 32281312. PMCID: PMC7152532.

34. Ashok K, Mathew AA, Thomas A, Mohan D, Gopalakrishna R, Reghu R. Clinical pharmacist’s interventions on medication adherence and knowledge of inflammatory bowel disease patients. J Young Pharm. 2017; 9:381–385. DOI: 10.5530/jyp.2017.9.76.

35. Moradkhani A, Kerwin L, Dudley-Brown S, Tabibian JH. Disease-specific knowledge, coping, and adherence in patients with inflammatory bowel disease. Dig Dis Sci. 2011; 56:2972–2977. DOI: 10.1007/s10620-011-1714-y. PMID: 21538016.

36. Nahon S, Lahmek P, Durance C, Olympie A, Lesgourgues B, Colombel JF, et al. Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18:2086–2091. DOI: 10.1002/ibd.22888. PMID: 22294486.

37. Park JW, Kim DH, Suh YS, Kim JB, Lee GH. Drug compliance according to severity of depressive symptoms in medically ill outpatients. Korean J Health Promot. 2007; 7:39–44.

38. Eaden JA, Abrams K, Mayberry JF. The Crohn’s and Colitis Knowledge Score: a test for measuring patient knowledge in inflammatory bowel disease. Am J Gastroenterol. 1999; 94:3560–3566. DOI: 10.1111/j.1572-0241.1999.01536.x. PMID: 10606319.

39. Kim JY, Yoon H, Hwang JS, Yang SK, Park SH, Loftus EV Jr. Comparison of disease-related knowledge of patients with inflammatory bowel disease between the West and the East using an updated questionnaire (IBD-KNOW). J Clin Gastroenterol. 2020; 54:720–724. DOI: 10.1097/MCG.0000000000001283. PMID: 31764490.

40. Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis. 2009; 15:1105–1118. DOI: 10.1002/ibd.20873. PMID: 19161177.